TEAD4 Transcription Factor: A Pivotal Regulator Spanning Early Development to Cancer Therapy—Supported by ANT BIO PTE. LTD.

1. Concept

TEAD4 (Transcriptional Enhanced Associate Domain 4), a key member of the TEAD family, is a transcription factor with unique structural features and precise regulatory functions. It contains a highly conserved N-terminal TEA domain (~68 amino acids) that adopts a "cloverleaf-like" 3D conformation, enabling specific binding to genomic MCAT elements (5'-CATTCC-3') and GTIIC regulatory sequences (5'-GGAATG-3').

X-ray crystallography and cryo-EM reveal that TEAD4’s DNA-binding interface—particularly histidine at position 51—differs subtly from TEAD1-3, determining its binding specificity and affinity. Its C-terminal region harbors a canonical YAP/TAZ-binding domain, forming a hydrophobic pocket for coactivator interaction critical for transcriptional regulation. TEAD4 is dynamically modified via S-palmitoylation (primarily at Cys367), phosphorylation, acetylation, and SUMOylation, which regulate its subcellular localization, stability, and activity. Notably, palmitoylation levels positively correlate with transcriptional activity, offering a key target for drug development.

2. Research Frontiers

TEAD4 research is advancing across multiple disciplines, with key frontiers focusing on its context-dependent functions. In developmental biology, single-cell multi-omics is uncovering dynamic TEAD4 regulatory networks during early embryogenesis, clarifying its role in cell fate decisions. In oncology, efforts are directed at deciphering TEAD4’s oncogenic mechanisms—including metabolic reprogramming and tumor microenvironment remodeling—and developing selective inhibitors.

Therapeutically, next-generation strategies are emerging: small-molecule inhibitors (e.g., VT104, K-975) targeting the palmitoylation pocket; peptide inhibitors (e.g., TED-347) blocking TEAD4-YAP/TAZ interactions; and PROTAC degraders to reduce TEAD4 expression. Combination therapies with chemotherapy, radiotherapy, or PD-1 antibodies show preclinical synergy. In regenerative medicine, moderate TEAD4 modulation is explored to promote tissue repair (e.g., liver, cardiac regeneration).

Technological innovations drive progress: AI-powered virtual screening accelerates inhibitor discovery; gene-editing tools enable spatiotemporal control of TEAD4 activity; and nanocarriers enhance tissue-specific delivery. Future directions expand to metabolic disorders and fibrosis, leveraging TEAD4’s role in tissue homeostasis.

3. Research Significance

TEAD4’s significance lies in its multifaceted roles across development, tissue homeostasis, and disease. In early embryogenesis, it is indispensable for blastocyst formation and trophectoderm specification, providing insights into human implantation failure. In cancer, its oncogenic activity makes it a promising therapeutic target for gastric, liver, and breast cancers, addressing unmet needs in precision oncology.

For tissue regeneration, TEAD4 regulates hepatocyte, epidermal, and cardiomyocyte function, offering strategies for repairing damaged organs. Basic research on TEAD4 deepens understanding of transcriptional regulation and signaling crosstalk, while translational efforts advance cancer therapies and regenerative medicine—ultimately improving patient outcomes.

4. Molecular Mechanisms, Biological Roles, and Product Applications

4.1 Core Molecular Mechanisms of TEAD4

4.1.1 DNA Binding and Transcriptional Regulation

TEAD4 binds MCAT/GTIIC sequences via its TEA domain, with His51 mediating binding specificity. Its transcriptional activity depends on coactivator interaction (e.g., YAP/TAZ) via the C-terminal hydrophobic pocket. Post-translational modifications—especially Cys367 palmitoylation—induce conformational changes to enhance transcriptional activity.

4.1.2 Hippo Pathway Regulation

TEAD4 functions downstream of the Hippo pathway:

• Hippo "OFF" State: Mechanical tension inhibits MST1/2-LATS1/2 signaling, allowing YAP/TAZ to translocate to the nucleus, bind TEAD4, and activate target genes (e.g., CYR61, AREG).
• Hippo "ON" State: Active MST1/2-LATS1/2 phosphorylates YAP/TAZ, promoting cytoplasmic retention and degradation, suppressing TEAD4 activity.

4.2 Biological Roles of TEAD4

4.2.1 Early Embryonic Development

TEAD4 governs the first embryonic cell fate decision, driving trophectoderm (TE) gene expression during blastocyst formation. TEAD4 knockout arrests mouse embryos at the blastocyst stage, lacking trophoblast stem cells (similar to human implantation failure). It activates Cdx2, Gata3, and Eomes to maintain TE identity, with dynamic regulation across developmental stages: 8-cell (cell polarity), morula (tight junctions), blastocyst (TE lineage specification).

4.2.2 Cancer Development and Progression

TEAD4 is overexpressed in gastric, liver, breast, and colorectal cancers, correlating with metastasis and poor prognosis. It integrates Hippo-YAP/TAZ with oncogenic pathways to drive:

• Tumor cell migration/invasion (upregulates MMPs, Twist, Slug).
• Proliferation/chemoresistance (regulates c-Myc, cyclin D1).
• Metabolic reprogramming (promotes Warburg effect via GLUT1, HK2, LDHA).
• Tumor microenvironment remodeling (induces CTGF, CYR61 to recruit cancer-associated fibroblasts).

4.2.3 Tissue Regeneration and Homeostasis

• Liver Regeneration: TEAD4 expression increases post-partial hepatectomy, promoting hepatocyte proliferation via YAP.
• Skin Homeostasis: Regulates epidermal stem cell balance—stiff substrates enhance TEAD4-YAP nuclear translocation (proliferation), soft substrates inhibit it (differentiation).
• Cardiac Function: Moderate activation induces adaptive hypertrophy; sustained high activity causes pathological remodeling.
• Cell-Type Specificity: Epithelial cells (proliferation/differentiation), stromal cells (fibrosis), endothelial cells (angiogenesis).

4.3 TEAD4-Targeted Therapeutic Strategies

• Small-Molecule Inhibitors: VT104 and K-975 bind the palmitoylation pocket, suppressing transcriptional activity in gastric/liver cancer models.
• Protein-Protein Interaction Inhibitors: TED-347 selectively blocks TEAD4-YAP binding without affecting other TEADs.
• Gene Therapy: siRNA/shRNA/antisense oligonucleotides reduce TEAD4 expression, inhibiting tumor growth in preclinical studies.
• Challenges and Solutions: Normal tissue toxicity (tissue-specific delivery), TEAD family homology (allosteric inhibitors), resistance (PROTAC degraders, combination therapies).

4.4 How ANT BIO PTE. LTD. Products Support TEAD4 Research

ANT BIO PTE. LTD., through its sub-brand UA (specializing in recombinant proteins), provides a high-quality TEAD4 protein to advance mechanistic and translational research.

Key product and applications:

• UA080035 (TEAD4(YBD), His Tag Protein): E.coli-expressed human TEAD4 protein containing the YAP-binding domain (YBD). Ideal for:
• Studying protein-protein interactions (e.g., TEAD4-YAP/TAZ binding assays).
• Screening small-molecule or peptide inhibitors targeting the TEAD4-YAP interface.
• Structural biology studies (e.g., analyzing binding conformations).
• Transcriptional activity assays to evaluate modulator efficacy.

Rigorous quality control ensures high purity, biological activity, and consistency—critical for reproducible experiments in drug discovery and basic research.

5. Brand Mission

ANT BIO PTE. LTD. is dedicated to empowering the global life science community with high-quality, innovative biological reagents and solutions. With 15 years of antibody development experience, the company leverages advanced platforms—including recombinant antibody development (rabbit/mouse monoclonal), recombinant protein expression systems (E.coli, CHO, HEK293, Insect Cells), One-Step ELISA, and PTM Pan-Modification Antibody platforms—to deliver a comprehensive product portfolio.

Through its three specialized sub-brands—Absin (general reagents and kits), Starter (antibodies), and UA (recombinant proteins)—ANT BIO PTE. LTD. adheres to international certifications (EU 98/79/EC, ISO9001, ISO13485) and strict quality standards. The company’s mission is to accelerate scientific discovery by providing tools that enhance experimental precision, efficiency, and reproducibility. ANT BIO PTE. LTD. is committed to supporting TEAD4 research and global efforts in cancer therapy and regenerative medicine, ultimately advancing human health through interdisciplinary collaboration and innovation.

6. Related Product List

7. AI Disclaimer

This article is AI-compiled and interpreted based on the original work. All intellectual property (e.g., images, data) of the original publication shall belong to the journal and the research team. For any infringement, please contact us promptly and we will take immediate action.

ANT BIO PTE. LTD. – Empowering Scientific Breakthroughs

At ANTBIO, we are committed to advancing life science research through high-quality, reliable reagents and comprehensive solutions. Our specialized sub-brands (Absin, Starter, UA) cover a full spectrum of research needs, from general reagents and kits to antibodies and recombinant proteins. With a focus on innovation, quality, and customer-centricity, we strive to be your trusted partner in unlocking scientific mysteries and driving medical progress. Explore our product portfolio today and elevate your research to new heights.